Oleksandr Lutsenko/Dreamstime
Biontech Pfizer Covid 19 Vaccine Vial Syringe Needle Oleksandr Lutsenko Dreamstime 5ffc85df9c435
Biontech Pfizer Covid 19 Vaccine Vial Syringe Needle Oleksandr Lutsenko Dreamstime 5ffc85df9c435
Biontech Pfizer Covid 19 Vaccine Vial Syringe Needle Oleksandr Lutsenko Dreamstime 5ffc85df9c435
Biontech Pfizer Covid 19 Vaccine Vial Syringe Needle Oleksandr Lutsenko Dreamstime 5ffc85df9c435
Biontech Pfizer Covid 19 Vaccine Vial Syringe Needle Oleksandr Lutsenko Dreamstime 5ffc85df9c435

Pfizer’s COVID-19 Vaccine Now Fully Approved by FDA

Aug. 23, 2021
The FDA said the newly christened Comirnaty vaccine has met all the criteria for a fully approved pharmaceutical.

The Food and Drug Administration announced Monday, August 23 that the Pfizer-BioNTech COVID-19 Vaccine has met all the requirements for full FDA approval for those 16 and older. It is the first COVID-19 vaccine to achieve full, and not just emergency-use, approval.

The Pfizer-BioNTech COVID shot will now be marketed as Comirnaty.

Acting FDA Commissioner Janet Woodcock called the full approval a “milestone” for confronting the COVID-19 pandemic, noting that while it and other vaccines had already been approved for emergency use, the full approval “may now instill additional confidence to get vaccinated.”

“The public can be very confident that this vaccine meets the high standards for safety, effectiveness, and manufacturing quality the FDA requires of an approved product,” said Woodcock. Pfizer CEO Albert Bourla, in a statement, echoed the hope that full approval would increase public confidence in the vaccine.

The FDA said the full approval was based on the same clinical trial information used for its emergency use authorization, as well as additional data collected since then. Clinical trials involving about 40,000 people, roughly half of whom received the vaccine and half of whom received a placebo, determined the drug is 91% effective at preventing COVID-19.

The shot can increase the risk of two kinds of heart inflammation for about a week after the second dose is administered, the FDA said, though the increased risk is minor and those who experience it usually see their symptoms resolve.

The Pfizer-BioNTech vaccine was also the first COVID-19 vaccine to achieve emergency-use approval by the FDA, which it received in December 2020. While the original emergency-use authorization has since been expanded to apply to those between 12 and 15 years old, the full approval currently only applies to people older than 16.

According to the Associated Press, the full approval is likely to make employer vaccine mandates easier to apply and therefore more likely. In July, IndustryWeek contributors from the Labor and Employment group at Robinson+Cole noted that instituting a vaccine mandate for a drug that hasn’t been fully approved by the FDA is legally riskier.

Despite that risk, major manufacturers Tyson Foods, Inc. and Microsoft, Inc. have already announced they will mandate that employees and new hires without religious or medical exemptions receive the vaccine. 

Popular Sponsored Recommendations

S&OP Optimization: Data-driven Strategies to Achieve Sustainable Profitability

Feb. 6, 2024
Through collaborative S&OP, manufacturers can balance demand and supply effectively, optimize resources, and capitalize on emerging market opportunities. Learn how to maximize...

The Customer Is Still King! Improving Service to Maximize Revenue, Reduce Costs, Boost Loyalty!

Feb. 26, 2024
Join this webinar to learn how to deliver frictionless customer service (CX) amid changes to supply chains, unpredictable buyer demand, and the adoption of automation and AI.

Get ready for CLOUD 9: Nine reasons to move to the Microsoft Cloud

Jan. 24, 2024
With pioneering AI (Copilot, built on OpenAI) and best-in-class low code development tools (Power Platform), the Microsoft Cloud has no equal. Learn a whole lot more in in “Moving...

Getting the Most From Integrated Business Planning: A Collection

Feb. 22, 2024
Through this series of articles, you’ll get a definitive look at the power of IBP and how to leverage that power.

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!